Ultragenyx Pharmaceutical Inc.
RARE
$14.31
-3.83%
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic diseases, with a portfolio including Crysvita, Dojolvi, and Mepsevii. It operates in the biotechnology sector, primarily serving patients in North America, Europe, and other global markets. The company is distinguished by its commitment to addressing debilitating conditions with high unmet medical need, leveraging a mix of internal R&D and strategic acquisitions. Currently, the stock is under significant pressure following a sharp decline in early September 2026, likely due to a major clinical or regulatory setback, which has overshadowed its recent revenue growth and commercial progress.…
RARE
Ultragenyx Pharmaceutical Inc.
$14.31
Investment Opinion: Should I buy RARE Today?
Rating: Hold. The consensus is Buy with an average target of $27.00, but the recent 44% drop and deep losses warrant caution. The thesis is that the company has strong revenue growth and a promising pipeline, but near-term uncertainties are high.
Sign up to view all
RARE 12-Month Price Forecast
The AI stance is neutral due to conflicting signals: strong revenue growth and low PS ratio are positive, but deep losses and a recent 44% drop create uncertainty. The stock is likely to remain volatile, with a slight upward bias if the market overreacted. Upgrade to bullish if revenue growth accelerates and pipeline news improves; downgrade to bearish if cash burn worsens or another setback occurs.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Ultragenyx Pharmaceutical Inc.'s 12-month outlook, with a consensus price target around $27.00 and implied upside of +88.7% versus the current price.
Average Target
$27.00
0 analysts
Implied Upside
+88.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$16 - $40
Analyst target range
The stock has coverage from 19 analysts, with a consensus recommendation of 'Buy' and an average target price of $27.00. This implies an upside of 76.5% from the current price of $15.30. The target range is wide, from $16.00 to $40.00, reflecting high uncertainty about the company's future. The low target suggests that even the most bearish analyst sees limited downside, while the high target implies significant upside if the pipeline succeeds. Recent ratings have been mostly positive, with actions like 'Overweight' and 'Buy' from firms such as Cantor Fitzgerald and RBC Capital, indicating that analysts remain optimistic despite the recent stock drop.
Bulls vs Bears: RARE Investment Factors
The bull case rests on strong revenue growth, high gross margins, and analyst optimism, with a consensus Buy and 76.5% upside. However, the bear case is compelling due to deep losses, negative cash flow, and a catastrophic one-day drop likely tied to a pipeline failure. Currently, bearish evidence dominates as the market has repriced the stock for significant risk. The key tension is whether the recent setback is a temporary blip or a fundamental blow to the pipeline, which will determine if the stock recovers or continues to decline.
Bullish
- Strong Revenue Growth: Q4 2025 revenue grew 25.55% YoY to $207M, driven by product sales and royalties. This demonstrates robust commercial execution and market demand for its rare disease therapies.
- High Gross Margins: Gross margin is 83.8%, reflecting the favorable economics of biopharmaceutical products. This provides a solid foundation for potential profitability as operating leverage improves.
- Analyst Consensus Buy: 19 analysts rate RARE a Buy with an average target of $27.00, implying 76.5% upside from the current price of $15.30. Recent actions from Cantor Fitzgerald and RBC Capital are positive.
- Low Valuation on Sales: Trailing PS ratio is 3.37x, historically low for a biotech with strong growth. This suggests the market is pricing in significant pessimism, offering potential value if pipeline succeeds.
Bearish
- Deep Unprofitability: Net loss of $129M in Q4 2025, with net margin of -62.3%. Operating expenses, especially R&D at $203M, continue to outpace revenue, leading to persistent cash burn.
- Sharp Stock Decline: Stock fell from $26.53 to $14.85 on September 3, 2026, a 44% drop in one day. This suggests a major clinical or regulatory setback, undermining near-term prospects.
- Negative Cash Flow: Free cash flow TTM is -$472M, indicating heavy cash consumption. The company may need to raise capital, diluting shareholders or increasing debt.
- High Valuation on Forward PE: Forward PE of 75.8x implies market expectations of profitability that may be unrealistic given current losses. This leaves little room for error.
RARE Technical Analysis
The stock is in a clear downtrend, with a 1-year price change of -51.09% and a 52-week range of $13.81 to $39.89. Currently trading at $15.30, the stock is near the bottom of its 52-week range, at approximately 5.6% above the low and 61.6% below the high. This positioning suggests that the market is pricing in significant negative sentiment, and the stock may be approaching oversold conditions, but the trend remains bearish.
Beta
0.32
0.32x market volatility
Max Drawdown
-60.8%
Largest decline past year
52-Week Range
$14-$40
Price range past year
Annual Return
-54.6%
Cumulative gain past year
| Period | RARE Return | S&P 500 |
|---|---|---|
| 1m | -46.6% | -1.4% |
| 3m | -40.3% | +3.3% |
| 6m | -32.9% | +15.1% |
| 1y | -54.6% | +17.2% |
| ytd | -39.4% | +11.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RARE Fundamental Analysis
Revenue has been growing strongly, with the latest quarter (Q4 2025) showing revenue of $207 million, a 25.55% year-over-year increase. This growth is driven by both product sales and royalty revenue, with Q4 product revenue at $101.7 million and royalty revenue at $105.6 million. However, the company remains deeply unprofitable, with a net loss of $129 million in Q4 2025 and a net margin of -62.3%. Gross margins are high at 83.8%, reflecting the nature of biopharmaceutical products, but operating expenses, particularly R&D at $203 million, continue to drive substantial losses.
Quarterly Revenue
$207000000.0B
2025-12
Revenue YoY Growth
+25.6%
YoY Comparison
Gross Margin
86.0%
Latest Quarter
Free Cash Flow
$-472000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RARE Overvalued?
Given the negative net income, the price-to-sales (PS) ratio is the most appropriate valuation metric. The trailing PS ratio is 3.37x, which is relatively low compared to historical levels, reflecting the recent price decline. The forward PE ratio is 75.8x, implying that analysts expect profitability in the near future, but this is speculative given the current loss trajectory. The EV/Sales ratio of 3.32x is consistent with the PS ratio, indicating that the market is valuing the company at a modest multiple of its revenue.
PE
-3.9x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-6.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financially, RARE is burning cash aggressively with a TTM free cash flow of -$472M and a net loss of $129M in Q4 2025. The company has a negative debt-to-equity ratio of -15.95, indicating a complex capital structure, and relies on external funding. With a current ratio of 2.48, liquidity is adequate, but continued losses could force dilutive financing or increased debt, pressuring the stock. The high R&D spending of $203M in Q4 is necessary for growth but also a major drain on resources.
FAQ
The key risks include clinical and regulatory setbacks, as evidenced by the 44% one-day drop, which could lead to further declines. Financial risks include a net loss of $129M in Q4 2025 and negative free cash flow of -$472M, which may force dilutive financing. Competitive risks arise from other biotechs targeting similar diseases, and macro risks include interest rate sensitivity. The most severe risk is a complete pipeline failure, which could push the stock below $10.
The 12-month forecast is uncertain, with a base case probability of 50% for a target range of $16-$27, a bull case of 25% for $27-$40, and a bear case of 25% for $10-$16. The most likely scenario is a gradual recovery to the analyst average of $27, assuming revenue growth continues and no further setbacks. However, the bear case is significant if the recent drop reflects a fundamental issue.
On a price-to-sales basis, RARE is trading at 3.37x, which is low for a biotech with 25% revenue growth, suggesting it may be undervalued. However, the forward PE of 75.8x implies the market expects profitability, which is speculative given current losses. Compared to its own history, the PS ratio is near the low end, indicating the market is pricing in significant risk. Overall, the stock appears fairly valued to undervalued on sales, but the earnings-based valuation is stretched.
RARE offers a compelling risk/reward with a consensus Buy and 76.5% upside to the average target, but the recent 44% drop highlights high risk. For investors with a high risk tolerance and a long-term view, it could be a good buy if they believe the pipeline setback is temporary. However, for conservative investors, the deep losses and negative cash flow make it a risky proposition. It is not a good buy for those seeking stability or income.
RARE is more suitable for long-term investment due to its high volatility and speculative nature. The stock has a beta of 0.315, which is low, but the recent price swings are extreme. Short-term trading is risky given the uncertainty. A minimum holding period of 3-5 years is recommended to allow pipeline developments to materialize. The company does not pay a dividend, so returns depend on capital appreciation.